22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Federal authorities have been looking into Under Armour’s accounting practices for the better part ...
Read More >
Coronavirus, recently named “COVID-19” by the World Health Organization, presents like a Hollywood...
Read More >
On Oct. 13, 2019, New York City enacted Int. 136-A (the Law), expanding the employment protections o...
Read More >
Deadline Coming Up for Calendar Year Plans to Submit Medicare Part D Notice to CMS- As you know, gr...
Read More >
Many construction contracts include a clause that allows an owner to terminate a contractor’s remai...
Read More >
Last summer, after a decade of fits and starts, and just minutes before the end of the 2018 legislat...
Read More >